Neoadjuvant therapy in Renal cell carcinoma

Created using ChatSlide

Renal cell carcinoma (RCC) treatment faces significant challenges, with a considerable recurrence rate post-surgery and intricate tumour presentations. This keynote addresses the critical need for neoadjuvant therapy in RCC, highlighting its potential to enhance surgical outcomes and combat resistant tumour behaviours. We will explore neoadjuvant immunotherapy's biological advantages, such as its ability to act as an antigen reservoir, prime T-cells, and possibly establish systemic immune...